1. Home
  2. EDIT vs BACC Comparison

EDIT vs BACC Comparison

Compare EDIT & BACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • BACC
  • Stock Information
  • Founded
  • EDIT 2013
  • BACC 2025
  • Country
  • EDIT United States
  • BACC United States
  • Employees
  • EDIT N/A
  • BACC N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • BACC
  • Sector
  • EDIT Health Care
  • BACC
  • Exchange
  • EDIT Nasdaq
  • BACC Nasdaq
  • Market Cap
  • EDIT 269.8M
  • BACC 279.6M
  • IPO Year
  • EDIT 2016
  • BACC 2025
  • Fundamental
  • Price
  • EDIT $4.01
  • BACC $10.04
  • Analyst Decision
  • EDIT Buy
  • BACC
  • Analyst Count
  • EDIT 11
  • BACC 0
  • Target Price
  • EDIT $4.56
  • BACC N/A
  • AVG Volume (30 Days)
  • EDIT 3.3M
  • BACC 21.7K
  • Earning Date
  • EDIT 11-03-2025
  • BACC 01-01-0001
  • Dividend Yield
  • EDIT N/A
  • BACC N/A
  • EPS Growth
  • EDIT N/A
  • BACC N/A
  • EPS
  • EDIT N/A
  • BACC N/A
  • Revenue
  • EDIT $38,901,000.00
  • BACC N/A
  • Revenue This Year
  • EDIT N/A
  • BACC N/A
  • Revenue Next Year
  • EDIT N/A
  • BACC N/A
  • P/E Ratio
  • EDIT N/A
  • BACC N/A
  • Revenue Growth
  • EDIT N/A
  • BACC N/A
  • 52 Week Low
  • EDIT $0.91
  • BACC $9.95
  • 52 Week High
  • EDIT $4.54
  • BACC $10.06
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 63.02
  • BACC N/A
  • Support Level
  • EDIT $3.32
  • BACC N/A
  • Resistance Level
  • EDIT $4.29
  • BACC N/A
  • Average True Range (ATR)
  • EDIT 0.35
  • BACC 0.00
  • MACD
  • EDIT -0.01
  • BACC 0.00
  • Stochastic Oscillator
  • EDIT 63.19
  • BACC 0.00

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About BACC Blue Acquisition Corp. Class A Ordinary Shares

Blue Acquisition Corp is a blank check company.

Share on Social Networks: